Skip to main content

Innovation Pharmaceuticals Inc. (IPIX)

OTCMKTS: IPIX · Delayed Price · USD
0.2750 -0.0144 (-4.98%)
Sep 17, 2021 9:40 AM EDT - Market open
Market Cap130.14M
Revenue (ttm)23,000
Net Income (ttm)n/a
Shares Out418.16M
EPS (ttm)-0.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume218,103
Open0.2706
Previous Close0.2894
Day's Range0.2706 - 0.3050
52-Week Range0.1550 - 0.5000
Beta-0.39
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About IPIX

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Cha...

IndustryBiotechnology
Employees4
Stock ExchangeOTCMKTS
Ticker SymbolIPIX
Full Company Profile

Financial Performance

Financial Statements

News

Last Patient Last Visit Completed in Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for COVID-19; T...

WAKEFIELD, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided additional information regarding t...

1 month ago - GlobeNewsWire

Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presente...

WAKEFIELD, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that antiviral research related t...

2 months ago - GlobeNewsWire

Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19

WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that it has achieved full patient...

3 months ago - GlobeNewsWire

Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19

WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Com...

3 months ago - GlobeNewsWire

Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19

WAKEFIELD, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that enrollment has surpassed 50...

4 months ago - GlobeNewsWire

Innovation Pharma's Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Disea...

WAKEFIELD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company's d...

5 months ago - GlobeNewsWire

Innovation Pharma Announces Brilacidin Abstract Accepted for Oral Presentation at the American Society for Virology's...

WAKEFIELD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that antiviral data related to B...

5 months ago - GlobeNewsWire

Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Tr...

WAKEFIELD, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that an independent Data Monitor...

5 months ago - GlobeNewsWire

Innovation Pharma's COVID-19 Drug Candidate Brilacidin Ranked in Top Three Percent of Compounds Predicted to Be Most ...

WAKEFIELD, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report today that a Machine Learni...

6 months ago - GlobeNewsWire

Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma's Phase 2 Clinical Trial of Brilacidin for C...

WAKEFIELD, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports that eight sites are now participa...

6 months ago - GlobeNewsWire

Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for Treating COVID-19 Scheduled to Begin Next Week

WAKEFIELD, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that the Company's Phase 2 clinic...

7 months ago - GlobeNewsWire

Innovation Pharmaceuticals' Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation

Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month

8 months ago - GlobeNewsWire

Innovation Pharmaceuticals COVID-19 Clinical Trial to Support Additional Development of Brilacidin as a “Pan-Coronavi...

WAKEFIELD, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces additional independent preliminar...

9 months ago - GlobeNewsWire